Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

Background: Lecanemab, an antibody directed at Aβ-protofibrils and plaque, showed meaningful delay in disease progression and biological effects consistent with disease modification in the phase 3 Clarity AD trial. Objective: The objective of this paper is to present efficacy and safety results in A...

Descrición completa

Detalles Bibliográficos

Principais autores:	Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, Marco Bozzali, Giancarlo Logroscino, Sarah Trafford, Shobha Dhadda, Michio Kanekiyo, Amanda Goodwin, Mark Hodgkinson, Steven Hersch, Michael Irizarry, Lynn Kramer, Lutz Froelich
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2026-04-01
Series:	The Journal of Prevention of Alzheimer's Disease
Assuntos:	Lecanemab Alzheimer’s disease Apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2274580726000312
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!